Epix Considers Selling Vasovist If Imaging Agent Clears FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA agrees to accept a “blinded re-read” of data on the vascular imaging agent as an NDA amendment after Epix appealed “approvable” requests for more studies.